Establishment Labs Extends NuSil Supply Agreement Through 2031

By Public Technologies
  • Establishment Labs signed a supply agreement amendment with NuSil Technology through wholly owned subsidiary ELSA on October 14, 2026.
  • The amendment extends the initial term from December 31, 2026, to December 31, 2031, effective January 1, 2027.
  • The agreement covers NuSil's manufacture and sale of medical-grade silicone for specified ELSA products.
  • Up to five automatic one-year renewals apply unless either party gives written notice by December 31 of the year before expiration.
  • Revised provisions cover payment and pricing, business continuity and intellectual property.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Establishment Labs Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115928), on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.